• Español
  • Patient Prescribing
    Information
    • Patient Information
    • Patient Information - English
    • Patient Information - Spanish

    • PRESCRIBING INFORMATION
    • Prescribing Information - English
    • Prescribing Information - Spanish

    • PRE-FILLED SYRINGE INSTRUCTIONS FOR USE
    • 200mg Dose - English
    • 200mg Dose - Spanish
    • 300mg Dose - English
    • 300mg Dose - Spanish

    • PRE-FILLED PEN INSTRUCTIONS FOR USE
    • 300mg Dose - English
    • 300mg Dose - Spanish
  • For Healthcare Professionals
  • For U.S. Residents Only
Moderate-to-Severe Asthma (Ages 12+)
  • Change Condition
  • About persistent
    asthma
  • about
    Dupixent
    • How DUPIXENT Works
    • Results With DUPIXENT
    • How DUPIXENT is Taken
  • Patient
    support
    • DUPIXENT MyWay® Program
    • Pricing and Insurance
    • Copay Card
    • Injection Support Center
    • Help Staying on Track
  • dupixent
    resources
    • Webinars
    • Frequently Asked Questions
    • Glossary
  • Patient
    Stories
  • For Healthcare Professionals
  • Español

Site Map

  • DUPIXENT Home
  • About Persistent Asthma
  • About DUPIXENT
    • How DUPIXENT Works
    • Results With DUPIXENT
    • How DUPIXENT is Taken
  • Patient Support
    • DUPIXENT MyWay® Program
    • Pricing and Insurance
    • Copay Card
    • Copay Card Enrollment
    • Injection Support Center
    • Help Staying on Track
  • DUPIXENT RESOURCES
    • Webinars
    • Frequently Asked Questions
    • Glossary
  • PATIENT STORIES

Important Safety
Information and Indication

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

  • have a parasitic (helminth) infection
  • are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with DUPIXENT.
  • are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
    • There is a pregnancy exposure registry for women who take DUPIXENT during pregnancy to collect information about the health of you and your baby. Your healthcare provider can enroll you or you may enroll yourself. To get more information about the registry call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.
  • are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines or use an asthma medicine. Do not change or stop your corticosteroid medicine or other asthma medicine without talking to your healthcare provider. This may cause other symptoms that were controlled by the corticosteroid medicine or other asthma medicine to come back.

DUPIXENT can cause serious side effects, including:

  • Allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: breathing problems, fever, general ill feeling, swollen lymph nodes, swelling of the face, mouth and tongue, hives, itching, fainting, dizziness, feeling lightheaded (low blood pressure), joint pain, or skin rash.
  • Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. It is not known whether this is caused by DUPIXENT. Tell your healthcare provider right away if you have: rash, shortness of breath, persistent fever, chest pain, or a feeling of pins and needles or numbness of your arms or legs.

The most common side effects in patients with asthma include injection site reactions, pain in the throat (oropharyngeal pain), and high count of a certain white blood cell (eosinophilia).

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed. Your healthcare provider will tell you how much DUPIXENT to inject and how often to inject it. DUPIXENT is an injection given under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give DUPIXENT injections, you or your caregiver should receive training on the right way to prepare and inject DUPIXENT. Do not try to inject DUPIXENT until you have been shown the right way by your healthcare provider. In children 12 years of age and older, it is recommended that DUPIXENT be administered by or under supervision of an adult.

Please see accompanying full Prescribing Information including Patient Information.

Indication

DUPIXENT is a prescription medicine used with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in people aged 12 years and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. DUPIXENT is not used to treat sudden breathing problems. It is not known if DUPIXENT is safe and effective in children with asthma under 12 years of age.

Site Map
Legal Disclaimer Information
Privacy Policy
 
Questions or comments?
Contact Sanofi US or call 1‑844‑643‑7346
to contact Regeneron Pharmaceuticals, Inc.
© 2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology.


Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

Enter your email address and we will send you your requested resource.

Success!

Your email is on its way. Be sure to check your inbox.

This DUPIXENT® (dupilumab) website is for U.S. healthcare professionals only. Click "continue" only if you are a U.S. healthcare professional.
US-DAS-1231(1)
Are you sure you want to leave?

Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to its website visitors and users; however, they take no responsibility for the information on any website but their own.

US-DAS-1231(1)
You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are moving to an Unbranded site


© 2002-2018 sanofi-aventis U.S. LLC. All rights reserved.

This site is intended for use by U.S. residents only.
DUP.21.01.0075    Last Update: February 2021

Share this information with friends and family.

E-mail This Page to a Friend

Your friend has shared this page about WhiteSite

Send a copy to myself (optional)
Your Email Has Been Sent

Your email has been sent to:

Message